|
Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.
|
Jun 2013
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.
|
Jun 2013
|
Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
|
Jun 2013
|
Immunotherapy
|
myelodysplastic syndromes (MDS)
|
|
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
|
Jun 2013
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
|
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
|
Jun 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Aplastic anemia: what have we learned from animal models and from the clinic.
|
Jun 2013
|
Semin Hematol
|
aplastic anemia
|
|
Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes.
|
Jun 2013
|
J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
Jun 2013
|
Bone Marrow Transplant
|
myelodysplastic syndromes (MDS)
|
|
ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RELEVANCE OF PRE-TRANSPLANT DISEASE STATUS.
|
Jun 2013
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
